Drug treatments for polycystic ovary syndrome

American Family Physician

Volumn 79, Issue 8, 2009, Pages 671-676

  Radosh, Lee ^a  

^a READING HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; APRI; CLOMIFENE; CLOMIFENE CITRATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; EFLORNITHINE; FINASTERIDE; FLUTAMIDE; INSULIN SENSITIZING AGENT; LETROZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SIBUTRAMINE; SPIRONOLACTONE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; HORMONE ANTAGONIST;

ARTHRALGIA; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EDEMA; ELECTROLYSIS; FEMALE INFERTILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HIRSUTISM; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LEUKOPENIA; LIBIDO; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW LEVEL LASER THERAPY; MENSTRUAL IRREGULARITY; MULTIPLE PREGNANCY; NAUSEA; OBESITY; OSTEOPOROSIS; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY; REVIEW; SIDE EFFECT; SKIN IRRITATION; SPOTTING; STROKE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHLEBITIS; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA; FEMALE;

CONTRACEPTIVES, ORAL; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPOGLYCEMIC AGENTS; POLYCYSTIC OVARY SYNDROME;

EID: 66149134463     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Pillai A, Bang H, Green C. Metformin and glitazones: do they really help PCOS patients? J Fam Pract. 2007;56(6):444-453. (Pubitemid 47015390)
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223- 1236. (Pubitemid 40397264)
3. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, eds. Polycystic Ovary Syndrome. Current issues in endocrinology and metabolism. Boston, Mass.: Blackwell Scientific Publications; 1992:377.
4. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
5. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 41, December 2002: polycystic ovary syndrome. Obstet Gynecol. 2002;100(6):1389- 1402.
6. Atay V, Cam C, Muhcu M, Cam M, Karateke A. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res. 2006;34(1):73-76.
7. Dehbashi S, Vafaei H, Parsanezhad MD, Alborzi S. Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome. Int J Gynaecol Obstet. 2006;93(1):44-48.
8. Palomba S, Orio F Jr, Falbo A, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(7):4068-4074. (Pubitemid 41058174)
9. Vaniqa (eflornithine hydrochloride) cream, 13.9% [prescibing information]. http://www.vaniqa.com/forms/Vaniqa-Prescription-Info.pdf. Accessed February 16, 2009.
10. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48(4):511-519. (Pubitemid 29174233)
11. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139-146. (Pubitemid 32268804)
12. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335(9):617-623. (Pubitemid 26277951)
13. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol. 2005;123(2):204-211. (Pubitemid 41728367)
14. Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1360-1365. (Pubitemid 40463988)
15. Sahin Y, Yirmibes U, Kelestimur F, Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2004;113(2):214-220. (Pubitemid 38456778)
16. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or anti-androgen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(9):4116-4123. (Pubitemid 37153708)
17. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(8):3835-3840. (Pubitemid 39071481)
18. Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006;86(2):385-397. (Pubitemid 44137446)
19. Cataldo NA, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2006;21(1):109-120. (Pubitemid 41794298)
20. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J. 2005;52(3):299-308. (Pubitemid 41003521)
21. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod. 2006;21(1):121-128. (Pubitemid 41794299)
22. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study [published correction appears in J Clin Endocrinol Metab. 2004;89(9):4655]. J Clin Endocrinol Metab. 2004;89(6):2756-2762. (Pubitemid 39244484)
23. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(1):89-94. (Pubitemid 32268796)
24. Penna IA, Canella PR, Reis RM, Silva de Sá MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod. 2005;20(9):2396-2401. (Pubitemid 41222483)
25. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol. 1999;141(4):361-367. (Pubitemid 29529489)
26. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril. 2003;80(5):1199-1204. (Pubitemid 37377751)
27. Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo.: Thomson Healthcare; updated periodically.
28. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2003;(4);CD000194.
29. Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril. 2005;84(6):1693-1697. (Pubitemid 41785666)
30. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52(5):587-594. (Pubitemid 30337084)
31. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002;147(2):217-221. (Pubitemid 34928619)
32. Yilmaz M, Karakoc A, Törüner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(3):154-160. (Pubitemid 41597556)
33. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552. (Pubitemid 351820473)
34. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci. 2000;900:245-252. (Pubitemid 30251475)
35. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332(7556):1485. (Pubitemid 44365283)
36. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod. 2004;19(11):2474-2483. (Pubitemid 39481270)
37. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305-309. (Pubitemid 32112106)
38. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod. 2006;21(6):1432-1435. (Pubitemid 44445018)
39. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053.
40. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551-566. (Pubitemid 46220816)
41. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951-953. (Pubitemid 37330397)
42. Siebert TI, Kruger TF, Steyn DW, Nosarka S. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril. 2006;86(5):1432-1437. (Pubitemid 44602073)
43. Neveu N, Granger L, St-Michel P, Lavoie HB. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril. 2007;87(1):113-120. (Pubitemid 46013871)
44. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008;111(4):959-968.
45. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141-146. (Pubitemid 29028311)
46. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2005;18(8):761-768. (Pubitemid 41309339)
47. Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2006;91(3):946-952. (Pubitemid 43357763)
48. Maciel GA, Soares Júnior JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril. 2004;81(2):355-360.
49. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593-4598. (Pubitemid 41159348)
50. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2005;90(2):729-733. (Pubitemid 40279187)
51. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;160(3):241-246. (Pubitemid 43374356)